An HPLC-PDA method for the simultaneous quantification of the HIV integrase inhibitor raltegravir, the new nonnucleoside reverse transcriptase inhibitor etravirine, and 11 other antiretroviral agents in the plasma of HIV-infected patients

Therapeutic Drug Monitoring

Volumn 30, Issue 6, 2008, Pages 662-669

  D'Avolio, Antonio ^a   Baietto, Lorena ^a   Siccardi, Marco ^a   Sciandra, Mauro ^a   Simiele, Marco ^a   Oddone, Valentina ^a   Bonora, Stefano ^a   Di Perri, Giovanni ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

ETV; HPLC; Human plasma; NNRTI; PDA; Protease inhibitors; Quantification; RGV; SPE; Therapeutic drug monitoring

Indexed keywords

AMPRENAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; DARUNAVIR; EFAVIRENZ; ETRAVIRINE; INDINAVIR; LOPINAVIR; M 8; NELFINAVIR; NEVIRAPINE; RALTEGRAVIR; RITONAVIR; SAQUINAVIR; UNCLASSIFIED DRUG;

ANALYTIC METHOD; ARTICLE; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG STABILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PHOTO DIODE ARRAY; PRIORITY JOURNAL; SOLID PHASE EXTRACTION;

ANTI-RETROVIRAL AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HUMANS; PYRIDAZINES; PYRROLIDINONES; SENSITIVITY AND SPECIFICITY;

EID: 57749207753     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/FTD.0b013e318189596d     Document Type: Article

References (43)

1. Taiwo BO, Hicks CB. Darunavir: an overview of an HIV protease inhibitor developed to overcome drug resistance. AIDS Read. 2007;17:151-161.
2. Correll T, Klibanov OM. Integrase inhibitors: A new treatment option for patients with human immunodeficiency virus infection. Pharmacotherapy. 2008;28:90-101.
3. Markowitz M, Nguyen BY, Gotuzzo E, et al. Rapid and durable antiretroviral effect of the HIV-1 integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection-results of a 48-week controlled study. JAIDS. 2007;46:125-133.
4. Andries K, Azijn H, Thielemans T, et al. TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1. Antimicrobial Agents and Chemotherapy. 2004;48:4680-4686.
5. Lazzarin A, Campbell T, Clotet B, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet. 2007;370:39-48.
6. Madruga JV, Cahn P, Grinsztejn B, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet. 2007;370:29-38.
7. Vingerhoets J, Azijn H, Fransen E, et al. TMC125 displays a high genetic barrier to the development of resistance: Evidence from in vitro selection experiments. Journal of Virology. 2005;79:12773-12782.
8. Back D, Gatti G, Fletcher C, et al. Therapeutic drug monitoring in HIV infection: current status and future directions. AIDS. 2002;16:S5-S37.
9. Back D, Gibbons S, Khoo S. An update on therapeutic drug monitoring for antiretroviral drugs. Ther Drug Monit. 2006;28:468-473.
10. Gazzard B. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2005). HIV Med. 2005;6:S1-S61.
11. Gazzard B, Bernard AJ, Boffito M, et al. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2006). HIV Med. 2006;7:487-503.
12. Aymard G, Legrand M, Trichereau N, et al. Determination of twelve antiretroviral agents in human plasma sample using reversed-phase high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl. 2000;744:227-240.
13. Choi SO, Rezk NL, Kashuba AD. High-performance liquid chromatography assay for the determination of the HIV-protease inhibitor tipranavir in human plasma in combination with nine other antiretroviral medications. J Pharm Biomed Anal. 2007;43:1562-1567.
14. Dailly E, Raffi F, Jolliet P. Determination of atazanavir and other antiretroviral drugs (indinavir, amprenavir, nelfinavir and its active metabolite M8, saquinavir, ritonavir, lopinavir, nevirapine and efavirenz) plasma levels by high performance liquid chromatography with UV detection. J Chromatogr B Analyt Technol Biomed Life Sci. 2004;813:353-358.
15. Marzolini C, Telenti A, Buclin T, et al. Simultaneous determination of the HIV protease inhibitors indinavir, amprenavir, saquinavir, ritonavir, nelfinavir and the non-nucleoside reverse transcriptase inhibitor efavirenz by high-performance liquid chromatography after solid-phase extraction. J Chromatogr B Biomed Sci Appl. 2000;740:43-58.
16. Notari S, Bocedi A, Ippolito G, et al. Simultaneous determination of 16 anti-HIV drugs in human plasma by high-performance liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci. 2006;831:258-266.
17. Pelerin H, Compain S, Duval X, et al. Development of an assay method for the detection and quantification of protease and non-nucleoside reverse transcriptase inhibitors in plasma and in peripherical blood mononuclear cells by liquid chromatography coupled with ultraviolet or tandem mass spectrometry detection. J Chromatogr B Analyt Technol Biomed Life Sci. 2005;819:47-57.
18. Sarasa-Nacenta M, Lopez-Pua Y, Mallolas J, et al. Simultaneous determination of the HIV-protease inhibitors indinavir, amprenavir, ritonavir, saquinavir and nelfinavir in human plasma by reversed-phase high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl. 2001;757:325-332.
19. Simon VA, Thiam MD, Lipford LC. Determination of serum levels of thirteen human immunodeficiency virus-suppressing drugs by high-performance liquid chromatography. J Chromatogr A. 2001;913:447-453.
20. Verbesselt R, Van Wijngaerden E, de Hoon J. Simultaneous determination of 8 HIV protease inhibitors in human plasma by isocratic high-performance liquid chromatography with combined use of UV and fluorescence detection: amprenavir, indinavir, atazanavir, ritonavir, lopinavir, saquinavir, nelfinavir and M8-nelfinavir metabolite. J Chromatogr B Analyt Technol Biomed Life Sci. 2007;845:51-60.
21. Center for Drug Evaluation and Research of the U.S. Department of Health and Human Services Food and Drug Administration. Guidance for Industry Bioanalytical Method Validation. [FDA]. May 2001; Available at: http://www.fda.gov/cder/guidance/4252fhl.htm. Accessed June 27, 2008.
22. Tibotec. TMC125 Investigator Brochure. Edition 11, TMC125 Investigator Brochure-Edition 11. 2006.
23. Tibotec. TMC125 IMPD-Quality Data. Edition 11, TMC125 IMPD-Quality Data-Edition 11. 2007.
24. Crommentuyn KM, Rosing H, Nan-Offeringa LG, et al. Rapid quantification of HIV protease inhibitors in human plasma by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry. J Mass Spectrom. 2003;38:157-166.
25. Crommentuyn KM, Rosing H, Hillebrand MJ, et al. Simultaneous quantification of the new HIV protease inhibitors atazanavir and tipranavir in human plasma by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2004;804:359-367.
26. D'Avolio A, Siccardi M, Sciandra M, et al. HPLC-MS method for the simultaneous quantification of the new HIV protease inhibitor darunavir, and 11 other antiretroviral agents in plasma of HIV-infected patients. J Chromatogr B Analyt Technol Biomed Life Sci. 2007;859:234-240.
27. Marzolini C, Beguin A, Telenti A, et al. Determination of lopinavir and nevirapine by high-performance liquid chromatography after solid-phase extraction: application for the assessment of their transplacental passage at delivery. J Chromatogr B Analyt Technol Biomed Life Sci. 2002;774:127-140.
28. Ter Hein R, Alderden-Los CG, Rosing H, et al. Fast and simultaneous determination of darunavir and eleven other antiretroviral drugs for therapeutic drug monitoring: method development and validation for the determination of all currently approved HIV protease inhibitors and non-nucleoside reverse transcriptase inhibitors in human plasma by liquid chromatography coupled with electrospray ionization tandem mass spectrometry. Rapid Commun Mass Spectrom. 2007;21:2505-2514.
29. Turner ML, Reed-Walker K, King JR, et al. Simultaneous determination of nine antiretroviral compounds in human plasma using liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci. 2003;784:331-341.
30. Merschman SA, Vallano PT, Wenning LA, et al. Determination of the HIV integrase inhibitor, MK-0518 (raltegravir), in human plasma using 96-well liquid-liquid extraction and HPLC-MS/MS. Journal of Chromatography B-Analytical Technologies in the Biomedical and Life Sciences. 2007;857:15-24.
31. Goldwirt L, Chhun S, Rey E, et al. Quantification of darunavir (TMC114) in human plasma by high-performance liquid chromatography with ultraviolet detection. J Chromatogr B Analyt Technol Biomed Life Sci. 2007;857:327-331.
32. Takahashi M, Kudaka Y, Okumura N, et al. The validation of plasma darunavir concentrations determined by the HPLC method for protease inhibitors. Biol Pharm Bull. 2007;30:1947-1949.
33. Merck & Co. MK-0518 Investigator Brochure. Edition 4.0, MK-0518 Investigator Brochure. 2007.
34. Knoll BM, Vento S, Temesgen Z. Etravirine. Drugs of Today. 2008;44:23-33.
35. Dickinson L, Robinson L, Tjia J, et al. Simultaneous determination of HIV protease inhibitors amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir and saquinavir in human plasma by high-performance liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2005;829:82-90.
36. Egge-Jacobsen W, Unger M, Niemann CU, et al. Automated, fast, and sensitive quantification of drugs in human plasma by LC/LC-MS: quantification of 6 protease inhibitors and 3 nonnucleoside transcriptase inhibitors. Ther Drug Monit. 2004;26:546-562.
37. Fan B, Bartlett MG, Stewart JT. Determination of lamivudine/stavudine/ efavirenz in human serum using liquid chromatography/electrospray tandem mass spectrometry with ionization polarity switch. Biomed Chromatogr. 2002;16:383-389.
38. Notari S, Mancone C, Tripodi M, et al. Determination of anti-HIV drug concentration in human plasma by MALDI-TOF/TOF. J Chromatogr B Analyt Technol Biomed Life Sci. 2006;833:109-116.
39. Rentsch KM. Sensitive and specific determination of eight antiretroviral agents in plasma by high-performance liquid chromatography-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2003;788:339-350.
40. Rezk NL, Crutchley RD, Yeh RF, et al. Full validation of an analytical method for the HIV-protease inhibitor atazanavir in combination with 8 other antiretroviral agents and its applicability to therapeutic drug monitoring. Ther Drug Monit. 2006;28:517-525.
41. Boehringer Ingelheim. Investigator Brochure. Investigator Brochure-Version n.5. 2002.
42. D'Avolio A, Sciandra M, Siccardi M, et al. A simple and sensitive assay for determining plasma tipranavir concentration in the clinical setting by new HPLC method. J Chromatogr B Analyt Technol Biomed Life Sci. 2007;848:374-378.
43. Kappelhoff BS, Crommentuyn KM, de Maat MM, et al. Practical guidelines to interpret plasma concentrations of antiretroviral drugs. Clin Pharmacokinet. 2004;43:845-853